Clinical Trial Update: Hypofractionated WPPT With HDR Boost [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on hypofractionated WPPT with HDR boost for prostate cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING